Sandy Spring Bank’s Acadia Pharmaceuticals ACAD Stock Holding History

Sandy Spring Bank’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1,500	Closed	-$43K	–	823
2016 Q4	$43K	Hold	1,500	–	–	﹤0.01%	458
2016 Q3	$48K	Hold	1,500	–	–	0.01%	436
2016 Q2	$49K	Hold	1,500	–	–	0.01%	437
2016 Q1	$42K	Hold	1,500	–	–	﹤0.01%	465
2015 Q4	$53K	Hold	1,500	–	–	0.01%	417
2015 Q3	$50K	Sell	1,500 -500	-25%	-$20.8K	0.01%	438
2015 Q2	$84K	Hold	2,000	–	–	0.01%	400
2015 Q1	$65K	Hold	2,000	–	–	0.01%	417
2014 Q4	$64K	Hold	2,000	–	–	0.01%	384
2014 Q3	$50K	Buy	+2,000	New	+$46.8K	0.01%	413

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Sandy Spring Bank's ACAD Position: Q1 2017 in Review

Sandy Spring Bank sold out of Acadia Pharmaceuticals (ACAD) in Q1 2017, closing a stake of 1,500 shares — an estimated $43K sold.

Sandy Spring Bank first reported a position in ACAD in Q3 2014 and held it in 10 quarters. The position peaked at $84K in Q2 2015. 219 funds tracked by Wall St. Rank hold ACAD as of Q1 2017.

Sandy Spring Bank reported no remaining Acadia Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Sandy Spring Bank sold 1,500 Acadia Pharmaceuticals shares in Q1 2017, an estimated $43K.
Sandy Spring Bank first reported a position in Acadia Pharmaceuticals in Q3 2014 and held it in 10 quarters.
Sandy Spring Bank's Acadia Pharmaceuticals position peaked at $84K in Q2 2015.
219 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2017.

Based on Sandy Spring Bank's 13F filing for Q1 2017, filed 10 May 2017.